logo
PROVIDERS
LABS
CROs
PAYORS
PATIENTS
ABOUT US
Schedule a Demo
Contact Us
Overview

Accelerate Trial Success with Targeted Patient Stratification

Leverage AI-driven pharmacogenomics to enhance recruitment, minimize dropouts, and boost outcome certainty in your clinical studies.
Schedule a Demo Contact us
Overview
Many clinical trials stumble due to ineffective patient selection and unforeseen variability in drug response. PGxAI’s Trial Optimization & Patient Stratification solution pinpoints the genetic and clinical markers that predict success—enabling CROs and sponsors to enroll the right participants from day one. By integrating multi-omics data, generative AI, and real-world evidence, PGxAI helps research teams streamline recruitment, tailor dosing protocols, and reduce costly trial failures.
•
Intelligent Cohort Identification: Find patients most likely to benefit or least likely to experience adverse events.
•
Adaptive Protocol Design: Adjust enrollment criteria or dosage mid-trial based on real-time AI insights.
•
Speedy Recruitment: Boost enrollment rates by targeting phenotypes and genotypes with high response potential.
•
Regulatory Confidence: Present data-driven rationales for patient inclusion/exclusion, strengthening your submissions to the FDA and global authorities.
Key Features
Serving every stakeholder in healthcare
Schedule a Demo Contact Us
1
icon
Genetic Marker Analysis
Focus on critical variants (e.g., CYP2C9, CYP2D6, SLCO1B1) linked to drug metabolism and efficacy, reducing unpredictable outcomes.
2
icon
Real-Time Data Integration
PGxAI aggregates patient demographics, biomarker data, and EHR inputs for dynamic patient matching and monitoring.
3
icon
Automated Screening Tools
Embed PGxAI’s algorithms in your EDC or screening platforms, instantly identifying high-priority participants and flagging at-risk subjects.
4
icon
Machine Learning Insights
Sophisticated AI models continuously refine cohort recommendations, minimizing late-phase surprises and expensive trial extensions.
5
icon
Flexible Across All Phases
From Phase I dose-finding to large-scale Phase III validation, PGxAI adapts its predictive models to meet each trial’s unique objectives.
Benefits
Benefits for CROs & Sponsors
Schedule a Demo Contact Us
Reduced Time-to-Market
Eliminate wasted cycles on suboptimal patient subsets and achieve faster interim analyses, ultimately shortening overall study timelines.
Lower Dropouts & Adverse Events
Target participants most likely to tolerate investigational drugs, cutting therapy discontinuations and emergency interventions.
Improved Statistical Power
Higher response rates or reduced variance means smaller sample sizes may suffice, trimming operational costs and complexities.
Enhanced Competitive Position
Offer sponsors a proven method to boost their trial’s probability of success, helping you attract repeat business and premier collaborations.
Success Metrics
Real-World Use Cases
Leverage AI-driven pharmacogenomics to enhance recruitment, minimize dropouts, and boost outcome certainty in your clinical studies.
Oncology Trials
Stratify participants by tumor genomics and drug-gene interactions, increasing response rates and progression-free survival metrics
Cardiovascular Studies
Identify variants affecting anticoagulant metabolism or statin-induced myopathy risk, lowering complication rates.
Psychiatric Research
Pinpoint gene-based predictors for antidepressant efficacy or adverse effects, raising retention and remission rates.
Whats next
Ready to Revolutionize Your Patient Selection?
Contact Our CRO Team
Discuss pilot programs, integration strategies, and ROI projections.
icon
Request a Demo
Experience PGxAI’s algorithms in a real-world trial scenario.
icon
Learn More
Explore how PGxAI aligns with your EDC and downstream analytics to deliver seamless, data-driven patient stratification.
icon